Home > About Us > Partnership Opportunities
Focus on pain management and enhanced drug delivery
Cytogel Pharma is currently considering partnering opportunities to license the proprietary Mu receptor agonist Cyt-1010 for the treatment of pain. Cyt-1010 has proven more potent than morphine with an improved side effect profile and less potential for causing addiction. The pre-clinical program is complete, and the INDA is in preparation.
Cytogel is also considering additional relationships to expand the application of the company's hydrogel technology for enhanced drug delivery. These hydrogels may be made temperature- and/or pH-sensitive and may carry many times their weight in drug, potentially improving control of drug release and precision of delivery.
If you are interested in exploring a corporate partnership with Cytogel Pharma or would like additional information, please email:
C. Dean Maglaris, CEO
partners@cytogelpharma.com
